Employment in the mental health industry has grown at a rapid pace since 2020, thanks in part to federal grants funding training programs to expand and improve the workforce https://t.co/LRBCVy4Qwr ...

Core Insights - The Cigna Group Foundation has announced a new round of grants totaling $9 million over three years, focusing on improving the mental health of military veterans by addressing social determinants of health, particularly housing stability [1][6][8] Grant Program Details - The 2025 grant application is open for eligible organizations in select states, closing on August 7, 2025 [2] - The foundation prioritizes grants in regions with high social determinant of health risks, including Arizona, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey, Pennsylvania, Tennessee, and Texas [3][6] - Goals of the grant program include increasing permanent housing for veterans, improving housing affordability through rental or mortgage assistance, and enhancing wraparound services for veterans transitioning from shelters [3][6] Veteran Mental Health Context - Military veterans face a higher risk of homelessness, with approximately 40,000 veterans without shelter on any given night, and a 7% increase in homelessness among veterans reported from 2022 to 2023 [4][6] Previous Funding Impact - In 2024, the first year of the grant program, $3 million was distributed to 23 organizations to support local veterans, focusing on stability and mental health [5][6] - Examples of funded initiatives include the Veterans Rapid Rehousing Program in Texas and financial assistance for veteran homeowners facing foreclosure in Tennessee [7] Broader Philanthropic Commitment - The Cigna Group Foundation has committed over $27 million in grants over three years to address youth and veteran mental health and reduce barriers to health equity [8]

Core Viewpoint - Centene Corporation is under investigation for potential violations of federal securities laws due to allegations of providing misleading business information, which has led to significant stock price decline following the withdrawal of its earnings guidance [1][4]. Company Overview - Centene is a managed healthcare company that specializes in government-sponsored programs such as Medicaid and Medicare, as well as health insurance plans on individual exchanges and commercial marketplaces [3]. Alleged Wrongdoing - On July 1, 2025, Centene announced its decision to withdraw its 2025 earnings guidance, citing declining market growth in 22 out of the 29 states it operates in. The company indicated that health risks in these states were much higher than previously anticipated in its risk adjustment calculations [4]. - Following this announcement, Centene's stock price dropped by $22.87 per share, representing a 40.37% decline, closing at $33.78 per share on July 2, 2025 [4].

Core Viewpoint - Centene Corporation is facing potential legal claims regarding violations of federal securities laws and unlawful business practices following a significant drop in stock price after withdrawing its 2025 earnings guidance [1][2]. Group 1: Company Performance - On July 2, 2025, Centene's stock price fell over 39.5% during intraday trading after the company announced the withdrawal of its 2025 earnings guidance due to higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - The company indicated that its Medicaid business has seen an increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Centene on behalf of its stockholders, focusing on whether the company has violated federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses or have information regarding these claims [3].

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit from investors who purchased securities during the specified Class Period, alleging misleading statements regarding Medicaid cost trends and financial guidance [1][3]. Group 1: Class Action Details - The class action represents investors who bought Elevance securities between April 18, 2024, and October 16, 2024, with a deadline of July 11, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance's management misled investors about the Medicaid redetermination process, claiming they were monitoring cost trends and that premium rates were adequate [3]. - It is claimed that the redetermination process resulted in a higher-risk Medicaid population, which was not accurately reflected in Elevance's financial projections or rate negotiations for 2024 [3].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors regarding the monitoring of cost trends related to the Medicaid "redetermination" process and assured that premium rates were sufficient to cover rising costs [4]. - It was revealed that the redetermination process led to a significant increase in the utilization of Medicaid members, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 earnings, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [7]. - Following this announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [8].

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., July 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has been adjour ...

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Centene Corporation ("Centene" or the "Company") (NYSE: CNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Centene and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On July 1, 2025, Centene ...

Company Overview - JPMorgan upgraded Phibro Animal Health Corporation (PAHC) due to strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfolio, which includes 37 product lines sold in about 80 countries and six manufacturing sites across the U.S., Italy, and China [1] - The acquisition is expected to enhance Phibro's profitability, improve EBITDA margins, and be accretive to adjusted earnings per share [1] Financial Performance - In Q3 2025, Phibro's sales reached $347.8 million, an increase of $84.6 million, or 32% year over year, although it missed the consensus estimate of $352.40 million [3] - Adjusted earnings for the same period were 63 cents, surpassing the consensus of 52 cents [3] Guidance and Market Outlook - Phibro raised its fiscal 2025 adjusted earnings per share guidance from $1.87-$2.01 to $1.96-$2.09, compared to the consensus of $1.94 [4] - The company revised its sales guidance from $1.25 billion-$1.30 billion to $1.26 billion-$1.29 billion, against a consensus of $1.28 billion [4] - Analyst Knyazkova noted that despite a strong performance in PAHC shares this year, there remains a favorable setup for further upside to estimates and attractive valuation [4] Industry Insights - The animal health performance is expected to exceed expectations for 2025, driven by strong demand, price increases, and healthy growth across medicated feed additives, nutritional specialties, and vaccines for 2026 [2] - While growth in livestock is slower than in companion animals, the livestock sector maintains strong fundamentals, including population growth, rising meat consumption, and limited impact from economic shifts [3]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy on its platform [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers and its executives made false or misleading statements and failed to disclose the risks associated with their practices, which jeopardized patient safety [2]. - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing deceptive promotion and selling of illegitimate versions of Wegovy [3]. Stock Impact - Following the announcement of the termination of the partnership, Hims & Hers' stock price fell by more than 34% [3]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [4].